Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials
COVID-19 and Cancer Care
Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
The ASCO Post Staff
Are you treating patients with advanced chronic myeloid leukemia (accelerated phase or blast crisis) any differently during the COVID-19 pandemic?
Recorded April 24, 2020.
The ASCO Post Staff
Eduardo L. Cazap, MD, PhD, of the Sociedad Latinoamericana y del Caribe de Oncología Médica, and an international editor on The ASCO Post Editorial Board, talks about the situation in Argentina treating patients with COVID-19, and the 10-country research effort led by the World Health Organization seeking to fast track research on the coronavirus. Filmed April 7, 2020.
The ASCO Post Staff
Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic?
Recorded April 21, 2020.
The ASCO Post Staff
William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.
The ASCO Post Staff
During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma?
Recorded April 24, 2020.